Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-07-19
2009-08-11
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S014800, C514S015800, C530S326000, C530S327000, C530S328000
Reexamination Certificate
active
07572765
ABSTRACT:
The present invention relates to conformationally constrained parathyroid hormone (PTH) analogs, and methods of preparing and using the PTH analogs. The invention provides novel PTH polypeptide derivatives containing amino acid substitutions at selected positions in the polypeptides. The invention provides derivatives of PTH (1-34), PTH(1-21), PTH(1-20), PTH(1-19), PTH(1-18), PTH(1-17), PTH(1-16), PTH(1-15), PTH(1-14), PTH(1-13), PTH(1-12), PTH(1-11) and PTH(1-1 0) polypeptides, wherein at least one residue in each polypeptide is a helix, preferably an a-helix, stabilizing residue. The invention also provides methods of making such peptides. Further, the invention encompasses compositions and methods for use in limiting undesired bone loss in a vertebrate at risk of such bone loss, in treating conditions that are characterized by undesired bone loss or by the need for bone growth, e.g. in treating fractures or cartilage disorders and for raising cAMP levels in cells where deemed necessary.
REFERENCES:
patent: 5393869 (1995-02-01), Nakagawa et al.
patent: 5496801 (1996-03-01), Holthuis et al.
patent: 5556940 (1996-09-01), Willick et al.
patent: 5616560 (1997-04-01), Geddes et al.
patent: 5693616 (1997-12-01), Krstenansky et al.
patent: 5695955 (1997-12-01), Krstenansky et al.
patent: 5717062 (1998-02-01), Chorev et al.
patent: 5723577 (1998-03-01), Dong
patent: 5798225 (1998-08-01), Krstenansky et al.
patent: 5814603 (1998-09-01), Oldenburg et al.
patent: 5977070 (1999-11-01), Piazza et al.
patent: 6066618 (2000-05-01), Holick
patent: 6417333 (2002-07-01), Bringhurst et al.
patent: 6495662 (2002-12-01), Gardella et al.
patent: 6537965 (2003-03-01), Bringhurst et al.
patent: 6541220 (2003-04-01), Jüppner et al.
patent: 6803213 (2004-10-01), Bringhurst et al.
patent: 2003/0144209 (2003-07-01), Bringhurst et al.
patent: 2003/0162256 (2003-08-01), Jüppner et al.
patent: 2003/0166838 (2003-09-01), Gardella et al.
patent: 0 477 885 (1992-04-01), None
patent: WO 87/01130 (1987-02-01), None
patent: WO 91/05050 (1991-04-01), None
patent: WO 92/01810 (1992-02-01), None
patent: WO 92/17602 (1992-10-01), None
patent: WO 95/11988 (1995-05-01), None
patent: WO 97/02834 (1997-01-01), None
patent: WO 98/05683 (1998-02-01), None
patent: WO 98/30590 (1998-07-01), None
patent: WO 99/18945 (1999-04-01), None
patent: WO 00/23594 (2000-04-01), None
patent: WO 00/31137 (2000-06-01), None
patent: WO 00/31266 (2000-06-01), None
patent: WO 00/32771 (2000-06-01), None
patent: WO 00/32775 (2000-06-01), None
patent: WO 00/39278 (2000-07-01), None
patent: WO 00/40698 (2000-07-01), None
patent: WO 01/23427 (2001-04-01), None
patent: WO 01/23521 (2001-04-01), None
patent: WO 03/009804 (2003-02-01), None
patent: WO 2004/067021 (2004-08-01), None
patent: WO 2004/093902 (2004-11-01), None
patent: WO 2004/022830 (2005-02-01), None
Luck et al. The (1-14) Fragment of Parathyroid Hormone PTH Activates Intact and Amino-Terminally Truncated PTH-1 Receptors. Mol. Endo. vol. 13, No. 5, pp. 670-680. 1999.
Bryant, S.D., et al., “Helix-Inducing α-Aminoisobutyric Acid in Opioid Mimetic Deltorphin C Analogues,”J. Med. Chem. 40:2579-2587, American Chemical Society (1997).
Cervini, L.A., et al., “Human Growth Hormone-Releasing hGHRH(1-29)-NH2: Systematic Structure-Activity Relationship Studies,”J. Med. Chem. 41:717-727, American Chemical Society (1998).
Moretto, A., et al., “(αMe)Nva: stereoselective syntheses and preferred conformations of selected model peptides,”J. Pept. Res. 56:283-297, Munksgaard International Publishers Ltd. (Nov. 2000).
Shimizu, N., et al., “Parathyroid Hormone (PTH)-(1-14) and -(1-11) Analogs Conformationally Constrained by α-Aminoisobutyric Acid Mediate Full Agonist Responses via the Juxtamembrane Region of the PTH-1 Receptor,”J. Biol. Chem. 276:49003-49012, The American Society for Biochemistry and Molecular Biology, Inc. (Dec. 2001).
Supplementary European Search Report for European Application No. 02 77 8189, completed Oct. 4, 2005.
Abou-Samra, A-B., et al., “Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: A single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium,”Proc. Natl. Acad. Sci. USA 89:2732-2736, National Academy of Sciences (1992).
Azarani, A., et al., “Structurally Diverse N-terminal Peptides of Parathyroid Hormone (PTH) and PTH-related Peptide (PTHRP) Inhibit the Na+/H+ Exchanger NHE3 Isoform by Binding to the PTH/PTHRP Receptor Type I and Activating Distinct Signaling Pathways,”J. Biol. Chem. 271:14931-14936, The American Society for Biochemistry and Molecular Biology, Inc. (1996).
Bergwitz, C., et al., “Residues in the Membrane-spanning and Extracellular Loop Regions of the Parathyroid Hormone (PTH)-2 Receptor Determine Signaling Selective for PTH and PTH-related Peptide,”J. Biol. Chem. 272:28861-28868, The American Society for Biochemistry and Molecular Biology, Inc. (1997).
Born, W. et al., “Inhibition of Parathyroid Hormone Bioactivity by Human Parathyroid Hormone (PTH)-(3-84) and PTH-(8-84) Synthesized inEscherichia coli,” Endocrinol. 123:1848-1853, The Endocrine Society (1988).
Chakravarthy, B.R., et al., “Parathyroid Hormone Fragment [3-34] Stimulates Protein Kinase C (PKC) Activity in Rat Osteosarcoma and Murine T-Lymphoma Cells,”Biochem. Biophys. Res. Comm. 171:1105-1110, Academic Press, Inc. (1990).
Chorev, M., et al., “Modifications of Position 12 in Parathyroid Hormone and Parathyroid Hormone Related Protein: Toward the Design of Highly Potent Antagonists,”Biochem. 29:1580-1586, American Chemical Society (1990).
Civitelli, R., et al., “PTH elevates inositol polyphosphates and diacylglycerol in a rat osteoblast-like cell line,”Am. J. Physiol. 255:E660-E667, American Physiological Society (1988).
Cohen, F.E., et al., “Analogues of Parathyroid Hormone Modified at Positions 3 and 6. Effects on Receptor Binding and Activation of Adenylyl Cyclase in Kidney and Bone,”J. Biol. Chem. 266:1997-2004, The American Society for Biochemistry and Molecular Biology, Inc. (1991).
Cole, J.A., et al., “Regulation of Sodium-Dependent Phosphate Transport by Parathyroid Hormone in Opossum Kidney Cells: Adenosine 3′, 5′-Monophosphate-Dependent and -Independent Mechanisms,”Endocrinol. 122:2981-2989, The Endocrine Society (1988).
Cunningham, B.C., and Wells, J.A., “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis,”Science 244:1081-1085, American Association for the Advancement of Science (1989).
Donahue, H.J., et al., “Differential Effects of Parathyroid Hormone and Its Analogues on Cytosolic Calcium Ion and cAMP Levels in Cultured Rat Osteoblast-like Cells,”J. Biol. Chem. 263:13522-13527, The American Society for Biochemistry and Molecular Biology, Inc. (1988).
Dunlay, R., and Hruska, K., “PTH receptor coupling to phospholipase C is an alternate pathway of signal transduction in bone and kidney,”Am. J. Physiol. 258:F223-F231, American Physiological Society (1990).
Fujimori, A., et al., “Structure-Function Relationship of Parathyroid Hormone: Activation of Phospholipase-C, Protein Kinase-A and -C in Osteosarcoma Cells,”Endocrinol. 130:29-36, The Endocrine Society (1992).
Gaich, G., et al., “Amino-Terminal Parathyroid Hormone-Related Protein: Specific Binding and Cytosolic Calcium Responses in Rat Insulinoma Cells,”Endocrinol. 132:1402-1409, The Endocrine Society (1993).
Gardella, T.J., et al., “Analysis of Parathyroid Hormone's Principal Receptor-Binding Region by Site-Directed Mutagenesis and Analog Design,”Endocrinol. 132:2024-2030, The Endocrine Society (1993).
Gardella, T.J., et al., “Converting Parathyroid Hormone-related Peptide (PTHrP) into a Potent PTH-2 Receptor Agonist,
Clark & Elbing LLP
Gupta Anish
The General Hospital Corporation
LandOfFree
Conformationally constrained parathyroid hormone (PTH) analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conformationally constrained parathyroid hormone (PTH) analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conformationally constrained parathyroid hormone (PTH) analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4068141